Literature DB >> 12602525

Preliminary observations on the effects of acute infusion of growth hormone on coronary vasculature and on myocardial function and energetics of an isolated and blood-perfused heart.

R Lorusso1, E Pasini, A Cargnoni, C Ceconi, M Volterrani, A Burattin, D Valle, R Ferrari, A Giustina.   

Abstract

Recent studies have shown that growth hormone (GH) deficiency may deteriorate post-ischemic myocardial reperfusion damage. Furthermore, GH has been reported to be a promising therapeutic option in the treatment of chronic myocardial dysfunction. However, the exact mechanisms of action of GH on the cardiovascular system, particularly in the acute setting, are still unclear. The aim of our study consisted of monitoring the acute effects of GH infusion on isolated blood-perfused rabbit heart according to dose-response pattern and during ischemic conditions to test its anti-ischemic property. Seven blood-donors perfused isolated hearts were used as experimental model. The mechanical and metabolic data of the isolated organs were continuously monitored. Under aerobic conditions, dose-response curves were initially tested after intracoronary infusion of GH at increasing dosages (1, 2, 3 mg/l). After a stabilization period, the effects of GH infusion (5 mg/kg) administered 30 minutes prior to acute global myocardial ischemia (30 minutes) were also investigated. At the doses tested, GH did not induce any changes either in the developed or in the diastolic pressures of the isolated organ. However, transient reduction of the coronary perfusion pressure was observed at the dosage of 3 mg/l. During the ischemia/reperfusion study, at the dosages used in this study, GH did not modify either the degree of stunning in the early reperfusion or the recovery of the developed pressure at the end of reperfusion. In addition, GH did not prevent either the increase of diastolic pressure during ischemia or the release of lactate and CPK during reperfusion. Tissue content of high-energy phosphates was also not changed by GH infusion. In our experimental model, acute GH infusion did not reduce the ischemic/reperfusion damage of the myocardium. However, GH transiently induced coronary vasodilation without modifying the myocardial contractility. Acute effects of GH appear, therefore, to predominantly relate to vascular dilation suggesting that the effects on myocardial contractility may require long-lasting intake being likely linked to enhancement of specific protein synthesis or gene expression of cardiac myocytes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12602525     DOI: 10.1007/BF03345113

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  17 in total

Review 1.  Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

Authors:  A Giustina; J D Veldhuis
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

2.  Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes.

Authors:  S Kinugawa; H Tsutsui; T Ide; R Nakamura; K Arimura; K Egashira; A Takeshita
Journal:  Cardiovasc Res       Date:  1999-07       Impact factor: 10.787

3.  Impaired spontaneous growth hormone secretion in severe dialated cardiomyopathy.

Authors:  A Giustina; R Lorusso; V Borghetti; G Bugari; V Misitano; O Alfieri
Journal:  Am Heart J       Date:  1996-03       Impact factor: 4.749

4.  Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure.

Authors:  W V Houck; L C Pan; S B Kribbs; M J Clair; G M McDaniel; R S Krombach; W M Merritt; C Pirie; J P Iannini; R Mukherjee; F G Spinale
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

5.  Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone.

Authors:  S D Anker; M Volterrani; C D Pflaum; C J Strasburger; K J Osterziel; W Doehner; M B Ranke; P A Poole-Wilson; A Giustina; R Dietz; A J Coats
Journal:  J Am Coll Cardiol       Date:  2001-08       Impact factor: 24.094

6.  Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure.

Authors:  A Giustina; M Volterrani; F Manelli; P Desenzani; C Poiesi; R Lorusso; A Giordano
Journal:  Am Heart J       Date:  1999-06       Impact factor: 4.749

Review 7.  Role of growth hormone in chronic heart failure. Therapeutic implications.

Authors:  M Volterrani; F Manelli; M Cicoira; R Lorusso; A Giustina
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

8.  Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats.

Authors:  G Rossoni; V De Gennaro Colonna; M Bernareggi; G L Polvani; E E Müller; F Berti
Journal:  J Cardiovasc Pharmacol       Date:  1998-08       Impact factor: 3.105

9.  Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.

Authors:  K J Osterziel; O Strohm; J Schuler; M Friedrich; D Hänlein; R Willenbrock; S D Anker; P A Poole-Wilson; M B Ranke; R Dietz
Journal:  Lancet       Date:  1998-04-25       Impact factor: 79.321

10.  A preliminary study of growth hormone in the treatment of dilated cardiomyopathy.

Authors:  S Fazio; D Sabatini; B Capaldo; C Vigorito; A Giordano; R Guida; F Pardo; B Biondi; L Saccà
Journal:  N Engl J Med       Date:  1996-03-28       Impact factor: 91.245

View more
  1 in total

1.  Growth hormone exerts acute vascular effects independent of systemic or muscle insulin-like growth factor I.

Authors:  Guolian Li; Juan-Pablo Del Rincon; Linda A Jahn; Yangsong Wu; Bruce Gaylinn; Michael O Thorner; Zhenqi Liu
Journal:  J Clin Endocrinol Metab       Date:  2008-01-08       Impact factor: 5.958

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.